Phase 3 Recruiting Network
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care …
Sponsor: Children's Oncology Group
NCT ID: NCT05602194
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center — Denver, Colorado
Phase 3 Recruiting Industry
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AM…
Sponsor: Daiichi Sankyo
NCT ID: NCT06578247
Sites in Colorado: - Colorado Blood Cancer Institute — Denver, Colorado
Phase 3 Recruiting Academic/Other
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…
Sponsor: PedAL BCU, LLC
NCT ID: NCT05183035
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Colorado: - Saint Joseph Hospital ( Site 0026) — Denver, Colorado
- Lutheran Medical Center ( Site 0027) — Golden, Colorado
- Intermountain Health St. Mary's Regional Hospital ( Site 0025) — Grand Junction, Colorado
Phase 3 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT07007312
Sites in Colorado: - University of Colorado — Aurora, Colorado
- Colorado Blood Cancer Institute — Denver, Colorado
Phase 3 Recruiting Industry
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse even…
Sponsor: AbbVie
NCT ID: NCT06428019
Sites in Colorado: - Rocky Mountain Cancer Centers - Aurora /ID# 267549 — Aurora, Colorado
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in pa…
Sponsor: BeOne Medicines
NCT ID: NCT06846671
Sites in Colorado: - Rocky Mountain Cancer Centers (Williams) Usor — Aurora, Colorado
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center — Denver, Colorado
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center — Denver, Colorado
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017…
Sponsor: Juno Therapeutics, a Subsidiary of Celgene
NCT ID: NCT03331198
Sites in Colorado: - Colorado Blood Cancer Institute — Denver, Colorado
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse ev…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05963074
Sites in Colorado: - Grand Valley Oncology — Grand Junction, Colorado
Phase 2 Recruiting Industry
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of tre…
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT06588478
Sites in Colorado: - Rocky Mountain Cancer Center — Aurora, Colorado
Phase 2 Recruiting Academic/Other
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the firs…
Sponsor: Etan Orgel
NCT ID: NCT05082519
Sites in Colorado: - Colorado Children's Hospital — Denver, Colorado
Phase 1, Phase 2 Recruiting Academic/Other
This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid …
Sponsor: Beat AML, LLC
NCT ID: NCT03013998
Sites in Colorado: - University of Colorado — Denver, Colorado
Phase 1, Phase 2 Recruiting Academic/Other
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-…
Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
NCT ID: NCT05849662
Sites in Colorado: - Children's Hospital of Colorado — Denver, Colorado
Phase 1, Phase 2 Recruiting Industry
The goal of the study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of TERN-701, a highly selective allosteric inhibitor of BCR-ABL1, in participants with previously treated chronic phase - chroni…
Sponsor: Terns, Inc.
NCT ID: NCT06163430
Sites in Colorado: - Rocky Mountain Cancer Centers, LLP — Lone Tree, Colorado
Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if participants treated with the experimental drug cusatuzumab added to venetoclax and azacitidine works to treat acute myeloid leukemia (AML) compared to venetoclax and azacitidine. Venetoclax a…
Sponsor: OncoVerity, Inc.
NCT ID: NCT06384261
Sites in Colorado: - University of Colorado Health - Anschutz Cancer Pavilion - Anschutz Medical Campus — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in Colorado: - Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016) — Aurora, Colorado
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transform…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT04728893
Sites in Colorado: - Colorado Blood Cancer Institute ( Site 2726) — Denver, Colorado
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
Sponsor: Vironexis Biotherapeutics Inc.
NCT ID: NCT06533579
Sites in Colorado: - Colorado Blood Cancer Institute — Denver, Colorado
Phase 2 Recruiting Academic/Other
Investigation of Relapsed or refractory AML with a monocytic phenotype after failure of hypomethylating agent+venetoclax
Sponsor: University of Colorado, Denver
NCT ID: NCT06232655
Sites in Colorado: - Universtiy of Colorado Hospital — Aurora, Colorado
Phase 1, Phase 2 Recruiting Academic/Other
This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally with the goals to expedite infusion to wider patient inclusion that includes those who were previously excluded, such as pediatric patients with …
Sponsor: University of Colorado, Denver
NCT ID: NCT04544592
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado
Phase 1 Recruiting Academic/Other
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT02074839
Sites in Colorado: - University of Colorado Denver — Aurora, Colorado
Phase 1 Recruiting Network
This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic…
Sponsor: Children's Oncology Group
NCT ID: NCT06247787
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado